Straumann Holding AG (STMN) AI Stock Analysis

• Market Cap: CHF12.09B
• Dividend Yield: 1.02%
• Average Volume (3M): 415.23K
• Price to Earnings (P/E): 41.7
• Beta (1Y): 1.13
• Revenue Growth: 4.49%
• EPS Growth: 45.08%
• Country: CH
• Employees: 11,342
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.33
• Shares Outstanding: 159,455,250
• 10 Day Avg. Volume: 293,178
• 30 Day Avg. Volume: 415,225
• PEG Ratio: -5.09
• Price to Book (P/B): 6.91
• Price to Sales (P/S): 5.73
• P/FCF Ratio: 45.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF90.62
• Price Target Upside: 19.55% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6
• EPS Forecast (FY): 3.03
• Revenue Forecast (FY): CHF2.71B

• Rating: 66 Neutral
• Price Target: CHF83.00 ▲(9.50% Upside)
• Action: Downgraded Date: 02/21/26
• Date: Action: Downgraded 02/21/26

The score reflects solid underlying financial strength and a positive, margin-improvement-oriented 2026 outlook, tempered by a 2025 profitability/cash-flow downshift. High valuation and only lukewarm technical momentum further cap the overall rating.

Positive Factors

Very strong gross and operating margins

Exceptionally high core gross margins (70%+) and a sustained core EBIT margin profile reflect a premium product mix, pricing power on implants and consumables, and operational scale. These margin levels underpin durable profitability even as the company invests in growth and digital adoption.

Strong commercial adoption and market share gains

Rapid adoption of new implants and digital platforms (1m+ iEXCEL implants; 15k AXS users) and share expansion to ~14% in a >CHF20bn TAM signal durable competitive advantages, wide clinical acceptance and multiple recurring revenue touchpoints across implants, ortho and digital workflows.

Solid cash generation and manageable leverage

Strong free cash flow (CHF290m, >11% of revenue) alongside moderate leverage (D/E ~0.30) provides financial flexibility to fund manufacturing transitions, R&D and targeted M&A while maintaining shareholder returns. This supports sustained investment without compromising solvency.

Negative Factors

Softening 2025 profitability and earnings momentum

Despite revenue growth, 2025 showed lower operating and net margins and declining reported earnings, indicating margin pressure from investments, transition costs or mix. If such profit dilution persists it could erode cash conversion and limit reinvestment capacity over the medium term.

China regulatory/VBP uncertainty and channel destocking

Uncertainty from China's VBP process and distributor destocking creates structural timing risk in a large market. Prolonged policy or channel disruptions could reduce procedure volumes and delay revenue recovery, impairing medium‑term growth in Asia until visibility on VBP clears.

High investment & transition costs weighing near-term margins

One-off and transition costs (large CapEx cycle, production transfers, ClearCorrect wind-down) plus restructuring/non-core charges compress near-term margins. If execution on production shifts and Smartee cost savings is slower, expected margin recovery could be delayed into 2027, pressuring cash returns.

Straumann Holding AG Business Overview & Revenue Model

Company Description

Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in tooth correction, replacement, and restoration, as well as to prevent tooth loss. The company offers dental implant systems for tissue and bone level; titanium, titanium alloy, ceramic, and mini dental implant systems; and guided and non-guided surgical instruments, as well as implant-borne prosthetics. It provides ceramic healing and screw retained abutments; intraoral scanning solutions; 3D printers; milling machines; and prevention products. In addition, it offers biomaterials, bone substitutes, membranes, biologics, and soft tissue management and oral healing products; digital solutions for dental labs, dentists, and centralized milling centers, as well as materials, third party systems, and guided surgery; surgical instruments comprising surgical and modular cassettes, guided instruments, implant maintenance products, bone block fixation sets, bonerings, titanium pin sets, and other cassettes; and edentulous, pro arch fixed, prosthetic, and mini implant solutions for edentulous patients. Further, it provides esthetic restorations that include ceramic implant monotypes, ceramic implants, abutments, biologics, and other solutions; and Emdogain for wound healing. Further, it offers systems Clear Correct aligners; and training and education services to its customers. The company provides its products to general dentists, specialists, and dental technicians and laboratories, as well as corporate customers, such as distributors, hospitals, universities, and dental service organizations in approximately 100 countries through a network of distribution subsidiaries and partners. Straumann Holding AG was founded in 1954 and is headquartered in Basel, Switzerland.

How the Company Makes Money

Straumann primarily makes money by selling dental products and solutions to dental clinics, dentists, orthodontists, and dental laboratories through a mix of direct sales organizations and third-party distributors (channel details by market are not fully available here). Key revenue streams include: (1) Dental implant solutions: sales of implant fixtures plus recurring companion products used in procedures, such as prosthetic components/abutments and other restorative parts, which can generate repeat purchases tied to procedure volumes. (2) Orthodontic solutions: sales of orthodontic products (e.g., clear aligner-related offerings and associated services, where applicable) used to plan and deliver tooth movement treatments. (3) Digital dentistry and services: revenue from digital workflows that support treatment planning and restoration manufacturing (e.g., software, scanning/planning, and other digital services where offered), as well as potentially related consumables; specific pricing structures (subscription vs. per-case vs. hardware bundling) are not available here. (4) Regenerative, biomaterials, and other dental consumables: sales of adjunct products used in implant and restorative procedures (category-level detail not available here). Straumann’s earnings are influenced by procedure demand in dental implantology and orthodontics, product mix (premium vs. value offerings), geographic expansion, and continued adoption of digital workflows across dental practices and labs. Significant partnerships, if any, are null.

Straumann Holding AG Financial Statement Overview

Summary

Good overall financial quality supported by steady revenue growth and very strong gross margins, plus a solid balance sheet with moderate leverage. Offsetting this, 2025 showed softer profitability (lower operating/net margins) and weakening free-cash-flow momentum and cash conversion, with debt rising versus 2024.

Income Statement

Revenue has grown steadily from 2023 to 2025 (about +8% over two years), and gross margins remain very strong (mid-to-high 60%s in 2025). However, profitability has softened versus 2024: operating margin and net margin both declined in 2025 (operating margin ~21% vs ~23% in 2024; net margin ~13.7% vs ~15.5%), and earnings are down year over year despite higher sales—suggesting cost pressure or mix/investment headwinds.

Balance Sheet

The balance sheet looks solid with moderate leverage: debt-to-equity is ~0.30 in 2025, still reasonable for the industry and well below the higher levels seen earlier (e.g., ~0.61 in 2020). Equity and assets have grown over time, supporting financial flexibility. A watch item is that total debt increased in 2025 versus 2024, and the 2025 return on equity is shown as 0.0 (likely missing/abnormal in the data), so recent capital efficiency is less clear from the provided metrics.

Cash Flow

Cash generation remains healthy with positive operating cash flow and free cash flow in 2025, but momentum is weakening: free cash flow declined in 2024 and fell further in 2025 (free cash flow growth -6.13% in 2025). Cash conversion is also less robust, with free cash flow running at ~65% of net income in both 2024 and 2025, indicating a meaningful gap between accounting profit and cash that warrants monitoring.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.60B	2.50B	2.41B	2.32B	2.02B
Gross Profit	1.79B	1.78B	1.79B	1.70B	1.53B
EBITDA	549.00M	726.15M	495.42M	678.33M	591.48M
Net Income	358.00M	388.32M	246.07M	434.79M	396.08M
Balance Sheet
Total Assets	3.82B	3.62B	3.40B	3.45B	3.05B
Cash, Cash Equivalents and Short-Term Investments	489.57M	383.07M	413.54M	697.11M	881.50M
Total Debt	650.72M	460.90M	412.35M	705.20M	711.66M
Total Liabilities	1.65B	1.58B	1.56B	1.60B	1.55B
Stockholders Equity	2.16B	2.04B	1.84B	1.85B	1.50B
Cash Flow
Free Cash Flow	329.78M	315.62M	316.61M	220.94M	440.97M
Operating Cash Flow	505.42M	483.39M	503.95M	416.38M	561.94M
Investing Cash Flow	-275.35M	-352.62M	-349.33M	-449.84M	-185.20M
Financing Cash Flow	-105.95M	-169.06M	-424.40M	-140.35M	-122.90M

Straumann Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 75.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:STMN, the sentiment is Negative. The current price of 75.8 is below the 20-day moving average (MA) of 86.41, below the 50-day MA of 92.84, and below the 200-day MA of 96.03, indicating a bearish trend. The MACD of -4.00 indicates Positive momentum. The RSI at 20.38 is Positive, neither overbought nor oversold. The STOCH value of 15.62 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:STMN.

Straumann Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALC	72 Outperform	CHF29.09B	38.35	4.44%	0.44%	0.39%	-12.46%
SOON	68 Neutral	CHF10.27B	17.11	―	2.14%	3.79%	-7.84%
STMN	66 Neutral	CHF12.09B	41.72	―	1.02%	4.49%	45.08%
GALD	63 Neutral	CHF33.37B	75.41	―	0.09%	6.22%	―
MED	62 Neutral	CHF1.08B	-168.33	―	―	7.29%	-112.70%
SKAN	55 Neutral	CHF985.90M	-45.23	―	0.77%	-3.45%	-49.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Straumann Holding AG Corporate Events

Straumann lifts dividend as 2025 growth and margins beat guidance

Straumann Group reported 2025 revenue of CHF 2.6 billion, representing 8.9% organic growth and confirming continued market-share gains across its global footprint. Performance was broad-based, with very strong growth in EMEA, solid improvement in North America, steady expansion in Asia-Pacific excluding China and double-digit gains in Latin America, while China remained weighed down by subdued patient traffic and procurement-related caution.

Profitability remained robust, with a core EBIT margin of 25.2% including currency effects and 26.5% at constant exchange rates, at the upper end of guidance, supported by efficiency gains and disciplined cost control. Growth was underpinned by major product launches such as the iEXCEL implant system, SIRIOS X3 intraoral scanner and the Straumann AXS cloud platform, as well as progress in transforming the orthodontics business via the ClearCorrect–Smartee partnership and extensive global training activities.

The group highlighted a strong performance culture, citing an employee engagement score of 80 that it links to its entrepreneurial, high-performance mindset. Reflecting disciplined capital allocation, the board proposed a 5% higher dividend of CHF 1.00 per share, and for 2026 the company guides to high single-digit organic revenue growth and a further core EBIT margin improvement despite ongoing market volatility.

The most recent analyst rating on (CH:STMN) stock is a Buy with a CHF120.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.

Straumann Group Sets Date for Full-Year 2025 Results Webcast

Straumann Group has scheduled the release of its full-year 2025 financial results for 18 February 2026, with management hosting an English-language live audio webcast for investors, analysts and media later that morning to discuss operational performance and provide an outlook. The event, which will include a Q&A session for pre-registered participants and a subsequently available recording, underscores the company’s ongoing engagement with capital markets and provides stakeholders with an opportunity to assess Straumann’s strategic and financial trajectory entering 2026.

The most recent analyst rating on (CH:STMN) stock is a Sell with a CHF89.00 price target. To see the full list of analyst forecasts on Straumann Holding AG stock, see the CH:STMN Stock Forecast page.